Sangui Biotech International (Sangui Biotech International) Risk Assessment

View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sangui Biotech International is: No Data: Cannot be evaluated.

Competitive Comparison of Sangui Biotech International's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangui Biotech International's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Risk Assessment falls into.

Sangui Biotech International (OTCPK:SGBI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sangui Biotech International Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines